Physician Recommended Nutriceuticals   Report issue

For profit Phase 3
Founded: Blue Bell PA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2012
NCT01653184
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

icosapent ethyl (vascepa) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1